Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
(Thomson Reuters ONE) -
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing
innovative medicines in urology and rheumatology, today announced that Richard
Pascoe, Chief Executive Officer, will present at the Rodman & Renshaw 18th
Annual Global Investment Conference on Tuesday, September 13, 2016, at 3:25 p.m.
Eastern Time. The conference will be held at The Lotte New York Palace Hotel in
New York, NY. Mr. Pascoe will provide an update on the Company's strategy and
development plans surrounding Vitaros®.
A live audio webcast of the presentation can be accessed via the Investor
Relations' section of the Company's website at www.apricusbio.com. Please log
in approximately 5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial product,
Vitaros®, for the treatment of erectile dysfunction, is approved in Europe, part
of the Middle East, and Canada, and is being commercialized in several countries
in Europe. In September 2015, Apricus in-licensed the U.S. development and
commercialization rights for Vitaros from Allergan. Apricus' marketing partners
for Vitaros include Recordati Ireland Ltd. (Recordati S.p.A.), Ferring
International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle,
Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one
active product candidate, RayVa(TM), its product candidate for the treatment of
the circulatory disorder Raynaud's phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros® is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.
CONTACT:
Institutional / Retail Investors: Matthew Beck
mbeck(at)troutgroup.com
The Trout Group LLC
(646) 378-2933
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 07.09.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 493259
Anzahl Zeichen: 2734
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 191 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
